TEST FORMS – introduction

These test forms is an overview of the data needed for submission of the WHO GFN EQAS results into the webtool.

#### **TEST FORM *– Salmonella***

Which method did you use for antimicrobial susceptibility testing of *Salmonella* in this EQAS?

MIC – microbroth dilution

MIC – macro dilution (tubes)

MIC – agar dilution

E-test

Disk diffusion

Tablets – Neo Sensitabs, Rosco

Which standard(s)/guideline(s) did you use when performing AST?

CLSI

EUCAST

ISO 20776-1:2006

TREK

Other

Which incubation conditions did you use?      °C/     h

#### Comments or additional information:      **TEST FORM *– Salmonella***

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Strain – *Salmonella* | Antimicrobial | Interpretation | | |
| ≤  > | Zone diameter (mm) or  MIC-value (mg/L) | S / I / R |
| WHO S-19.1  \_\_\_\_\_     \_\_\_\_\_  Serogroup  \_\_\_\_\_     \_\_\_\_\_  Serotype  \_\_\_\_\_     \_\_\_\_\_  Antigenic formula | Ampicillin, AMP |  |  |  |
| Cefotaxime, FOT |  |  |  |
| Cefoxitin, FOX |  |  |  |
| Ceftazidime, TAZ |  |  |  |
| Ceftriaxone, CRO |  |  |  |
| Chloramphenicol, CHL |  |  |  |
| Ciprofloxacin, CIP |  |  |  |
| Colistin, COL |  |  |  |
| Gentamicin, GEN |  |  |  |
| Meropenem, MERO |  |  |  |
| Nalidixic acid, NAL |  |  |  |
| Sulfamethoxazole, SMX |  |  |  |
| Sulfamethoxazole-trimethoprim, SXT |  |  |  |
| Tetracycline, TET |  |  |  |
| Trimethoprim, TMP |  |  |  |

All strains displaying reduced susceptibility to cefotaxime (FOT), ceftazidime (TAZ), and/or ceftriaxone (CRO) could additionally be tested for ampC, ESBL- or carbapenemase-production. See further description in the protocol section 3.3.

|  |
| --- |
| Did you test for ESBL-production (ESBL-, AmpC, or carbapenemase-phenotypes)?  Yes  No  Is the strain an ESBL-, AmpC, or carbapenemase-phenotype?  Yes  No  Please select the detected ESBL-phenotype (see guideline in the EQAS protocol) [please select one option]  ESBL-phenotype  ESBL+AmpC-phenotype  AmpC-phenotype  Carbapenemase-phenotype  Other phenotype |
|
|
|

Comments:

#### **TEST FORM *– Salmonella***

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Strain – *Salmonella* | Antimicrobial | Interpretation | | |
| ≤  > | Zone diameter (mm) or  MIC-value (mg/L) | S / I / R |
| WHO S-19.2  \_\_\_\_\_     \_\_\_\_\_  Serogroup  \_\_\_\_\_     \_\_\_\_\_  Serotype  \_\_\_\_\_     \_\_\_\_\_  Antigenic formula | Ampicillin, AMP |  |  |  |
| Cefotaxime, FOT |  |  |  |
| Cefoxitin, FOX |  |  |  |
| Ceftazidime, TAZ |  |  |  |
| Ceftriaxone, CRO |  |  |  |
| Chloramphenicol, CHL |  |  |  |
| Ciprofloxacin, CIP |  |  |  |
| Colistin, COL |  |  |  |
| Gentamicin, GEN |  |  |  |
| Meropenem, MERO |  |  |  |
| Nalidixic acid, NAL |  |  |  |
| Sulfamethoxazole, SMX |  |  |  |
| Sulfamethoxazole-trimethoprim, SXT |  |  |  |
| Tetracycline, TET |  |  |  |
| Trimethoprim, TMP |  |  |  |

All strains displaying reduced susceptibility to cefotaxime (FOT), ceftazidime (TAZ), and/or ceftriaxone (CRO) could additionally be tested for ampC, ESBL- or carbapenemase-production. See further description in the protocol section 3.3.

|  |
| --- |
| Did you test for ESBL-production (ESBL-, AmpC, or carbapenemase-phenotypes)?  Yes  No  Is the strain an ESBL-, AmpC, or carbapenemase-phenotype?  Yes  No  Please select the detected ESBL-phenotype (see guideline in the EQAS protocol) [please select one option]  ESBL-phenotype  ESBL+AmpC-phenotype  AmpC-phenotype  Carbapenemase-phenotype  Other phenotype |
|
|
|

Comments:

#### **TEST FORM *– Salmonella***

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Strain – *Salmonella* | Antimicrobial | Interpretation | | |
| ≤  > | Zone diameter (mm) or  MIC-value (mg/L) | S / I / R |
| WHO S-19.3  \_\_\_\_\_     \_\_\_\_\_  Serogroup  \_\_\_\_\_     \_\_\_\_\_  Serotype  \_\_\_\_\_     \_\_\_\_\_  Antigenic formula | Ampicillin, AMP |  |  |  |
| Cefotaxime, FOT |  |  |  |
| Cefoxitin, FOX |  |  |  |
| Ceftazidime, TAZ |  |  |  |
| Ceftriaxone, CRO |  |  |  |
| Chloramphenicol, CHL |  |  |  |
| Ciprofloxacin, CIP |  |  |  |
| Colistin, COL |  |  |  |
| Gentamicin, GEN |  |  |  |
| Meropenem, MERO |  |  |  |
| Nalidixic acid, NAL |  |  |  |
| Sulfamethoxazole, SMX |  |  |  |
| Sulfamethoxazole-trimethoprim, SXT |  |  |  |
| Tetracycline, TET |  |  |  |
| Trimethoprim, TMP |  |  |  |

All strains displaying reduced susceptibility to cefotaxime (FOT), ceftazidime (TAZ), and/or ceftriaxone (CRO) could additionally be tested for ampC, ESBL- or carbapenemase-production. See further description in the protocol section 3.3.

|  |
| --- |
| Did you test for ESBL-production (ESBL-, AmpC, or carbapenemase-phenotypes)?  Yes  No  Is the strain an ESBL-, AmpC, or carbapenemase-phenotype?  Yes  No  Please select the detected ESBL-phenotype (see guideline in the EQAS protocol) [please select one option]  ESBL-phenotype  ESBL+AmpC-phenotype  AmpC-phenotype  Carbapenemase-phenotype  Other phenotype |
|
|
|

Comments:

#### **TEST FORM *– Salmonella***

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Strain – *Salmonella* | Antimicrobial | Interpretation | | |
| ≤  > | Zone diameter (mm) or  MIC-value (mg/L) | S / I / R |
| WHO S-19.4  \_\_\_\_\_     \_\_\_\_\_  Serogroup  \_\_\_\_\_     \_\_\_\_\_  Serotype  \_\_\_\_\_     \_\_\_\_\_  Antigenic formula | Ampicillin, AMP |  |  |  |
| Cefotaxime, FOT |  |  |  |
| Cefoxitin, FOX |  |  |  |
| Ceftazidime, TAZ |  |  |  |
| Ceftriaxone, CRO |  |  |  |
| Chloramphenicol, CHL |  |  |  |
| Ciprofloxacin, CIP |  |  |  |
| Colistin, COL |  |  |  |
| Gentamicin, GEN |  |  |  |
| Meropenem, MERO |  |  |  |
| Nalidixic acid, NAL |  |  |  |
| Sulfamethoxazole, SMX |  |  |  |
| Sulfamethoxazole-trimethoprim, SXT |  |  |  |
| Tetracycline, TET |  |  |  |
| Trimethoprim, TMP |  |  |  |

All strains displaying reduced susceptibility to cefotaxime (FOT), ceftazidime (TAZ), and/or ceftriaxone (CRO) could additionally be tested for ampC, ESBL- or carbapenemase-production. See further description in the protocol section 3.3.

|  |
| --- |
| Did you test for ESBL-production (ESBL-, AmpC, or carbapenemase-phenotypes)?  Yes  No  Is the strain an ESBL-, AmpC, or carbapenemase-phenotype?  Yes  No  Please select the detected ESBL-phenotype (see guideline in the EQAS protocol) [please select one option]  ESBL-phenotype  ESBL+AmpC-phenotype  AmpC-phenotype  Carbapenemase-phenotype  Other phenotype |
|
|
|

Comments:

#### **TEST FORM *– Salmonella***

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Strain – *Salmonella* | Antimicrobial | Interpretation | | |
| ≤  > | Zone diameter (mm) or  MIC-value (mg/L) | S / I / R |
| WHO S-19.5  \_\_\_\_\_     \_\_\_\_\_  Serogroup  \_\_\_\_\_     \_\_\_\_\_  Serotype  \_\_\_\_\_     \_\_\_\_\_  Antigenic formula | Ampicillin, AMP |  |  |  |
| Cefotaxime, FOT |  |  |  |
| Cefoxitin, FOX |  |  |  |
| Ceftazidime, TAZ |  |  |  |
| Ceftriaxone, CRO |  |  |  |
| Chloramphenicol, CHL |  |  |  |
| Ciprofloxacin, CIP |  |  |  |
| Colistin, COL |  |  |  |
| Gentamicin, GEN |  |  |  |
| Meropenem, MERO |  |  |  |
| Nalidixic acid, NAL |  |  |  |
| Sulfamethoxazole, SMX |  |  |  |
| Sulfamethoxazole-trimethoprim, SXT |  |  |  |
| Tetracycline, TET |  |  |  |
| Trimethoprim, TMP |  |  |  |

All strains displaying reduced susceptibility to cefotaxime (FOT), ceftazidime (TAZ), and/or ceftriaxone (CRO) could additionally be tested for ampC, ESBL- or carbapenemase-production. See further description in the protocol section 3.3.

|  |
| --- |
| Did you test for ESBL-production (ESBL-, AmpC, or carbapenemase-phenotypes)?  Yes  No  Is the strain an ESBL-, AmpC, or carbapenemase-phenotype?  Yes  No  Please select the detected ESBL-phenotype (see guideline in the EQAS protocol) [please select one option]  ESBL-phenotype  ESBL+AmpC-phenotype  AmpC-phenotype  Carbapenemase-phenotype  Other phenotype |
|
|
|

Comments:

#### **TEST FORM *– Salmonella***

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Strain – *Salmonella* | Antimicrobial | Interpretation | | |
| ≤  > | Zone diameter (mm) or  MIC-value (mg/L) | S / I / R |
| WHO S-19.6  \_\_\_\_\_     \_\_\_\_\_  Serogroup  \_\_\_\_\_     \_\_\_\_\_  Serotype  \_\_\_\_\_     \_\_\_\_\_  Antigenic formula | Ampicillin, AMP |  |  |  |
| Cefotaxime, FOT |  |  |  |
| Cefoxitin, FOX |  |  |  |
| Ceftazidime, TAZ |  |  |  |
| Ceftriaxone, CRO |  |  |  |
| Chloramphenicol, CHL |  |  |  |
| Ciprofloxacin, CIP |  |  |  |
| Colistin, COL |  |  |  |
| Gentamicin, GEN |  |  |  |
| Meropenem, MERO |  |  |  |
| Nalidixic acid, NAL |  |  |  |
| Sulfamethoxazole, SMX |  |  |  |
| Sulfamethoxazole-trimethoprim, SXT |  |  |  |
| Tetracycline, TET |  |  |  |
| Trimethoprim, TMP |  |  |  |

All strains displaying reduced susceptibility to cefotaxime (FOT), ceftazidime (TAZ), and/or ceftriaxone (CRO) could additionally be tested for ampC, ESBL- or carbapenemase-production. See further description in the protocol section 3.3.

|  |
| --- |
| Did you test for ESBL-production (ESBL-, AmpC, or carbapenemase-phenotypes)?  Yes  No  Is the strain an ESBL-, AmpC, or carbapenemase-phenotype?  Yes  No  Please select the detected ESBL-phenotype (see guideline in the EQAS protocol) [please select one option]  ESBL-phenotype  ESBL+AmpC-phenotype  AmpC-phenotype  Carbapenemase-phenotype  Other phenotype |
|
|
|

Comments:

#### **TEST FORM *– Salmonella***

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Strain – *Salmonella* | Antimicrobial | Interpretation | | |
| ≤  > | Zone diameter (mm) or  MIC-value (mg/L) | S / I / R |
| WHO S-19.7  \_\_\_\_\_     \_\_\_\_\_  Serogroup  \_\_\_\_\_     \_\_\_\_\_  Serotype  \_\_\_\_\_     \_\_\_\_\_  Antigenic formula | Ampicillin, AMP |  |  |  |
| Cefotaxime, FOT |  |  |  |
| Cefoxitin, FOX |  |  |  |
| Ceftazidime, TAZ |  |  |  |
| Ceftriaxone, CRO |  |  |  |
| Chloramphenicol, CHL |  |  |  |
| Ciprofloxacin, CIP |  |  |  |
| Colistin, COL |  |  |  |
| Gentamicin, GEN |  |  |  |
| Meropenem, MERO |  |  |  |
| Nalidixic acid, NAL |  |  |  |
| Sulfamethoxazole, SMX |  |  |  |
| Sulfamethoxazole-trimethoprim, SXT |  |  |  |
| Tetracycline, TET |  |  |  |
| Trimethoprim, TMP |  |  |  |

All strains displaying reduced susceptibility to cefotaxime (FOT), ceftazidime (TAZ), and/or ceftriaxone (CRO) could additionally be tested for ampC, ESBL- or carbapenemase-production. See further description in the protocol section 3.3.

|  |
| --- |
| Did you test for ESBL-production (ESBL-, AmpC, or carbapenemase-phenotypes)?  Yes  No  Is the strain an ESBL-, AmpC, or carbapenemase-phenotype?  Yes  No  Please select the detected ESBL-phenotype (see guideline in the EQAS protocol) [please select one option]  ESBL-phenotype  ESBL+AmpC-phenotype  AmpC-phenotype  Carbapenemase-phenotype  Other phenotype |
|
|
|

Comments:

#### **TEST FORM *– Salmonella***

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Strain – *Salmonella* | Antimicrobial | Interpretation | | |
| ≤  > | Zone diameter (mm) or  MIC-value (mg/L) | S / I / R |
| WHO S-19.8  \_\_\_\_\_     \_\_\_\_\_  Serogroup  \_\_\_\_\_     \_\_\_\_\_  Serotype  \_\_\_\_\_     \_\_\_\_\_  Antigenic formula | Ampicillin, AMP |  |  |  |
| Cefotaxime, FOT |  |  |  |
| Cefoxitin, FOX |  |  |  |
| Ceftazidime, TAZ |  |  |  |
| Ceftriaxone, CRO |  |  |  |
| Chloramphenicol, CHL |  |  |  |
| Ciprofloxacin, CIP |  |  |  |
| Colistin, COL |  |  |  |
| Gentamicin, GEN |  |  |  |
| Meropenem, MERO |  |  |  |
| Nalidixic acid, NAL |  |  |  |
| Sulfamethoxazole, SMX |  |  |  |
| Sulfamethoxazole-trimethoprim, SXT |  |  |  |
| Tetracycline, TET |  |  |  |
| Trimethoprim, TMP |  |  |  |

All strains displaying reduced susceptibility to cefotaxime (FOT), ceftazidime (TAZ), and/or ceftriaxone (CRO) could additionally be tested for ampC, ESBL- or carbapenemase-production. See further description in the protocol section 3.3.

|  |
| --- |
| Did you test for ESBL-production (ESBL-, AmpC, or carbapenemase-phenotypes)?  Yes  No  Is the strain an ESBL-, AmpC, or carbapenemase-phenotype?  Yes  No  Please select the detected ESBL-phenotype (see guideline in the EQAS protocol) [please select one option]  ESBL-phenotype  ESBL+AmpC-phenotype  AmpC-phenotype  Carbapenemase-phenotype  Other phenotype |
|
|
|

Comments:      

#### **TEST FORM – *E. coli* reference strain**

Susceptibility testing of *E. coli* reference strain ATCC 25922

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial | Zone diameter (mm) or  MIC-value (mg/L) |
| *E. coli* ATCC 25922 | Ampicillin, AMP |  |
| Cefotaxime, FOT |  |
| Cefoxitin, FOX |  |
| Ceftazidime, TAZ |  |
| Ceftriaxone, CRO |  |
| Chloramphenicol, CHL |  |
| Ciprofloxacin, CIP |  |
| Colistin, COL |  |
| Gentamicin, GEN |  |
| Meropenem, MERO |  |
| Nalidixic acid, NAL |  |
| Sulfamethoxazole, SMX |  |
| Sulfamethoxazole-trimethoprim, SXT |  |
| Tetracycline, TET |  |
| Trimethoprim, TMP |  |